Drug name - Spravato

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592207 JANSSEN PHARMS Intranasal administration of ketamine to treat depression Mar, 2027

(4 years from now)

US8785500 JANSSEN PHARMS Intranasal administration of ketamine to treat depression Jul, 2031

(8 years from now)

US10869844 JANSSEN PHARMS Methods for the treatment of depression Sep, 2035

(12 years from now)

US11173134 JANSSEN PHARMS Methods for the treatment of depression Sep, 2035

(12 years from now)

Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient

Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant; Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84 mg of esketamine 2x weekly for 4 weeks in conjunction with an oral antidepressant; treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase in conjunction with an oral antidepressent; treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase followed by a maintenance phase of 56mg or 84 mg weekly or 1x every two weeks in conjunction with an oral antidepressant; Treatment of trd in conjunction with an oral antidepressant by nasally administering 56mg or 84mg of esketamine in a maintenance phase weekly or 1x every two weeks to adults who have been administered esketamine in a induction phase for about 4 weeks

Dosage: SPRAY;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 28MG BASE SPRAY;NASAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.